Resources

Explore our online resource catalog to discover publications, presentations, tools, and related resources for global health practitioners, decision-makers, advocates, and more.

All resources

Read our latest

2396 Result s
2396 Result s
    Date
    From
    To
  1. Through the Accra Declaration and the African Union Champion Roadmap on Reproductive, Maternal, Newborn, Child and Adolescent Health (RMNCAH) 2026–2030, African leaders have committed to ending preventable maternal deaths. Products such as heat-stable carbetocin and the Ellavi balloon tamponade show that maternal health tools can be designed for low-resource settings, and in Ellavi’s case, made in Africa. The critical question is whether global research and development is producing the maternal health tools African women need, and whether those tools can reach them in time.The third report in the R&D Blindspots series from PATH and Impact Global Health answers: not yet. Drawing on R&D funding data, product pipelines, clinical trial records, and regulatory and manufacturing analysis, the report looks at four conditions that drive much of maternal and newborn death: postpartum hemorrhage, preeclampsia and eclampsia, maternal iron deficiency anemia, and preterm labor.The findings show a field that is underfunded, fragile, and largely shaped outside the continent:Sub-Saharan Africa accounts for 70% of global maternal deaths, yet R&D for these four conditions received just US$306 million between 2023 and 2025. That is around 1% of the global health R&D funding tracked by G-FINDER.Two funders based outside the continent provided three-quarters of that funding, while industry contributed just 1%.Three-quarters of preeclampsia diagnostics and 88% of preterm labor diagnostics need a laboratory. That limits their use in primary care, where African women receive antenatal care.Only 0.3% of the US$38 billion in global health clinical trial funding tracked since 2007 went to trials that included pregnant and lactating women.African institutions led just 22 of the 62 maternal health trials in sub-Saharan Africa.Even proven products designed for African settings face slow regulatory, procurement, and manufacturing pathways, delaying their reach to women who need them.This highlights a critical blindspot: neither the Accra Declaration nor the AU Champion Roadmap identifies the maternal health products or research priorities needed to meet its goals. Closing these R&D and access gaps is essential to delivering on the promise to end preventable maternal deaths and reach those goals.The report identifies priority actions, including:adding a priority list of maternal health products to Accra Declaration implementation plans, covering low-cost postpartum hemorrhage devices and point-of-care diagnostics;making the inclusion of pregnant and lactating women the default in clinical trials that funders support;using regulatory reliance and joint assessments to fast-track maternal health products already recommended by WHO; andaggregating demand across borders through joint procurement and pooled forecasting, giving manufacturers the volume and predictability they need to invest.Maternal Health R&D Gaps is the third publication in the Blindspots series, produced jointly by Impact Global Health and PATH. Launched at the International Conference on Public Health in Africa (CPHIA 2026) in Addis Ababa, the report underscores the urgency of closing maternal health R&D gaps.
    Published: November 2026
    Resource Page
    Part of a Series, Brief, Report
  2. This document highlights the health impact of a variety of medical devices and health technologies advanced by the Medical Devices and Health Technologies Program with public- and private-sector partners in use around the world, such as SoloShot syringes, HEATmarker® Vaccine Vial Monitors, Nifty Feeding Cups, and BD Uniject injection systems. Many of these innovations have been produced at a scale of millions or billions of units. Also featured are more recent product introductions addressing critical global health needs.
    Published: November 2026
    Resource Page
    Fact Sheet
  3. This is a simple, Excel-based tool for assessing and comparing costs of human papillomavirus (HPV) vaccination programs with each HPV vaccine product available in the global market. It aims to help national-level policymakers specifically in countries eligible for support from Gavi, the Vaccine Alliance, compare products and estimate vaccination program costs for different HPV vaccines, exploring up to four different vaccine options at a time.The tool calculates cold chain volume and costs annually and for a total period of five years. Cost estimates are composed of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost plus cost of delivery). Cost estimates are provided separately for the country perspective and the combined country and Gavi perspective.It is important to note that cost is only one consideration when selecting an HPV vaccine product, and users involved in decision-making around new vaccine introduction/switch or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. Please be sure to check out this seven-minute tutorial video, which is in English, with French and Spanish subtitled versions also available. The tool is available to download in multiple languages. If you have additional questions or need support, contact PATH's Health Economics & Outcomes Research team: HEOR@path.org.NOTE: Please refer to this web page for the most up-to-date version of the calculator, which is periodically updated to reflect the evolving vaccine landscape.
    Published: November 2026
    Resource Page
    Part of a Series, Training Material
  4. This is a simple, Excel-based tool for assessing and comparing costs of human papillomavirus (HPV) vaccination programs with each HPV vaccine product available in the global market. It aims to help national-level policymakers specifically in middle-income countries compare products and estimate vaccination program costs for different HPV vaccines, exploring up to four different vaccine options at a time. The tool calculates cold chain volume and costs annually and for a total period of five years. Cost estimates are composed of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost and cost of delivery).It is important to note that cost is only one consideration when selecting an HPV vaccine product, and users involved in decision-making around new vaccine introduction/switch or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. The tool is available to download in multiple languages. Please be sure to check out this six-minute tutorial video, which is in English, with French and Spanish subtitled versions also available. If you have additional questions or need support, contact PATH’s Health Economics & Outcomes Research team: HEOR@path.org.NOTE: Please refer to this web page for the most up-to-date version of the calculator, which is periodically updated to reflect the evolving vaccine landscape.
    Published: November 2026
    Resource Page
    Part of a Series, Training Material
  5. To lower the risk of cancers associated with human papillomavirus (HPV), Burkina Faso introduced HPV vaccination into its routine immunization program. The campaign provided nine-year-old girls with vaccine access, in accordance with the current immunization schedule. The initiative was launched off in April 2022 following a successful demonstration phase in 2017. Learn more about the key takeaways from multistakeholder consultation workshops.
    Published: October 2026
    Resource Page
    Part of a Series, Fact Sheet